168 related articles for article (PubMed ID: 23567466)
1. Reduction of melting temperature and enthalpy of drug crystals: theoretical aspects.
Hasa D; Voinovich D; Perissutti B; Grassi G; Fiorentino S; Farra R; Abrami M; Colombo I; Grassi M
Eur J Pharm Sci; 2013 Sep; 50(1):17-28. PubMed ID: 23567466
[TBL] [Abstract][Full Text] [Related]
2. Prediction of solubility curves and melting properties of organic and pharmaceutical compounds.
Nordström FL; Rasmuson AC
Eur J Pharm Sci; 2009 Feb; 36(2-3):330-44. PubMed ID: 19022383
[TBL] [Abstract][Full Text] [Related]
3. Capturing the crystal: prediction of enthalpy of sublimation, crystal lattice energy, and melting points of organic compounds.
Salahinejad M; Le TC; Winkler DA
J Chem Inf Model; 2013 Jan; 53(1):223-9. PubMed ID: 23215043
[TBL] [Abstract][Full Text] [Related]
4. Estimation of Melting Points of Organics.
Yalkowsky SH; Alantary D
J Pharm Sci; 2018 May; 107(5):1211-1227. PubMed ID: 29274821
[TBL] [Abstract][Full Text] [Related]
5. Use of enthalpy and Gibbs free energy to evaluate the risk of amorphous formation.
Hsieh DS; Sarsfield BA; Davidovich M; DiMemmo LM; Chang SY; Kiang S
J Pharm Sci; 2010 Sep; 99(9):4096-105. PubMed ID: 20564337
[TBL] [Abstract][Full Text] [Related]
6. Estimating the melting point, entropy of fusion, and enthalpy of fusion of organic compounds via SPARC.
Whiteside TS; Hilal SH; Brenner A; Carreira LA
SAR QSAR Environ Res; 2016 Aug; 27(8):677-701. PubMed ID: 27586365
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of predictive models for stable solid solution formation.
Albers J; Matthée K; Knop K; Kleinebudde P
J Pharm Sci; 2011 Feb; 100(2):667-80. PubMed ID: 20803574
[TBL] [Abstract][Full Text] [Related]
8. Solubility of molecular crystals: polymorphism in the light of solubility theory.
Bennema P; van Eupen J; van der Wolf BM; Los JH; Meekes H
Int J Pharm; 2008 Mar; 351(1-2):74-91. PubMed ID: 17980982
[TBL] [Abstract][Full Text] [Related]
9. The solubility behaviour and thermodynamic relations of the three forms of Venlafaxine free base.
van Eupen JT; Westheim R; Deij MA; Meekes H; Bennema P; Vlieg E
Int J Pharm; 2009 Feb; 368(1-2):146-53. PubMed ID: 18996456
[TBL] [Abstract][Full Text] [Related]
10. Thermal expansion of organic crystals and precision of calculated crystal density: a survey of Cambridge Crystal Database.
Sun CC
J Pharm Sci; 2007 May; 96(5):1043-52. PubMed ID: 17455328
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the ideal solubility (crystal-liquid fugacity ratio) of organic compounds.
Yalkowsky SH; Wu M
J Pharm Sci; 2010 Mar; 99(3):1100-6. PubMed ID: 19739108
[TBL] [Abstract][Full Text] [Related]
12. Metastability and transformation of polymorphic crystals in biodegradable poly(butylene adipate).
Gan Z; Kuwabara K; Abe H; Iwata T; Doi Y
Biomacromolecules; 2004; 5(2):371-8. PubMed ID: 15002996
[TBL] [Abstract][Full Text] [Related]
13. Temperature and solvent effects in the solubility of some pharmaceutical compounds: Measurements and modeling.
Mota FL; Carneiro AP; Queimada AJ; Pinho SP; Macedo EA
Eur J Pharm Sci; 2009 Jun; 37(3-4):499-507. PubMed ID: 19406228
[TBL] [Abstract][Full Text] [Related]
14. A general method for cultivating single crystals from melt microdroplets.
Ou X; Li X; Rong H; Yu L; Lu M
Chem Commun (Camb); 2020 Sep; 56(69):9950-9953. PubMed ID: 32706014
[TBL] [Abstract][Full Text] [Related]
15. Impact of nanosizing on solubility and dissolution rate of poorly soluble pharmaceuticals.
Murdande SB; Shah DA; Dave RH
J Pharm Sci; 2015 Jun; 104(6):2094-2102. PubMed ID: 25821105
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the phase diagrams of chiral praziquantel.
Liu Y; Wang X; Wang JK; Ching CB
Chirality; 2006 May; 18(4):259-64. PubMed ID: 16521119
[TBL] [Abstract][Full Text] [Related]
17. On the size and shape dependence of the solubility of nano-particles in solutions.
Kaptay G
Int J Pharm; 2012 Jul; 430(1-2):253-7. PubMed ID: 22486956
[TBL] [Abstract][Full Text] [Related]
18. An investigation into the influence of counterion on the properties of some amorphous organic salts.
Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
[TBL] [Abstract][Full Text] [Related]
19. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds.
Trasi NS; Baird JA; Kestur US; Taylor LS
J Phys Chem B; 2014 Aug; 118(33):9974-82. PubMed ID: 25076138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
